Please use this identifier to cite or link to this item: 10.3390/medicina57030200
Title: Our Evolving Understanding of ME/CFS
Authors: Friedman, Kenneth J.
Murovska, Modra
Pheby, Derek F.H.
Zalewski, Paweł
Institute of Microbiology and Virology
Keywords: Longhaul COVID-19;ME/CFS;Pathophysiology;1.6 Biological sciences;3.3 Health sciences;1.1. Scientific article indexed in Web of Science and/or Scopus database;General Medicine
Issue Date: 26-Feb-2021
Citation: Friedman , K J , Murovska , M , Pheby , D F H & Zalewski , P 2021 , ' Our Evolving Understanding of ME/CFS ' , Medicina (Lithuania) , vol. 57 , no. 3 , 200 , pp. 1-5 . https://doi.org/10.3390/medicina57030200
Abstract: The potential benefits of the scientific insights gleaned from years of treating ME/CFS for the emerging symptoms of COVID-19, and in particular Longhaul-or Longhauler-COVID-19 are discussed in this opinion article. Longhaul COVID-19 is the current name being given to the long-term sequelae (symptoms lasting beyond 6 weeks) of SARS-CoV-2 infection. Multiple case definitions for ME/CFS exist, but post-exertional malaise (PEM) is currently emerging as the ‘hallmark’ symptom. The inability to identify a unique trigger of ME/CFS, as well as the inability to identify a specific, diagnostic laboratory test, led many physicians to conclude that the illness was psychosomatic or non-existent. However, recent research in the US and the UK, championed by patient organizations and their use of the internet and social media, suggest underlying pathophysiologies, e.g., oxidative stress and mitochondrial dysfunction. The similarity and overlap of ME/CFS and Longhaul COVID-19 symptoms suggest to us similar pathological processes. We put forward a unifying hypothesis that explains the precipitating events such as viral triggers and other documented exposures: For their overlap in symptoms, ME/CFS and Longhaul COVID-19 should be described as Post Active Phase of Infection Syndromes (PAPIS). We further propose that the underlying biochemical pathways and pathophysiological processes of similar symptoms are similar regardless of the initiating trigger. Exploration of the biochemical pathways and pathophysiological processes should yield effective therapies for these conditions and others that may exhibit these symptoms. ME/CFS patients have suffered far too long. Longhaul COVD-19 patients should not be subject to a similar fate. We caution that failure to meet the now combined challenges of ME/CFS and Longhaul COVID-19 will impose serious socioeconomic as well as clinical consequences for patients, the families of patients, and society as a whole.
Description: Funding Information: The IOM report of 2015 also declared ME/CFS a disease, as opposed to its classification of being a syndrome [14], based upon the severity of the illness and its unique set of symptoms [5]. Nevertheless, and important for the hypothesis put forward here, ME/CFS remains technically a syndrome: a collection of symptoms of unknown etiology. Much work directed towards identifying the underlying pathology has been undertaken across the world, in many locations including North America and Europe, where the European ME/CFS Research Network (EUROMENE), established in 2006, has, with funding from the European Union’s COST (Cooperation in Science and Technology) program, helped to address this issue (COST project CA15111) [15]. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
DOI: 10.3390/medicina57030200
ISSN: 1010-660X
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:
File SizeFormat 
Opinion_our_evolving_understanding_of_me.pdf230.57 kBAdobe PDFView/Openopen_acces_unlocked


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.